ALLERGAN INC Income Statement

Ask AI

Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated statements of earnings

In millions of USD, except per-share amounts

	FY2014 12 months to Dec 31, 2014	FY2013 12 months to Dec 31, 2013	FY2012 12 months to Dec 31, 2012	FY2011 12 months to Dec 31, 2011	FY2010 12 months to Dec 31, 2010
Revenues:
Product net sales
Other revenues
Total revenues
Operating costs and expenses:
Cost of sales (excludes amortization of intangible assets)
Selling, general and administrative
Research and development
Amortization of acquired intangible assets
Legal settlement
Amortization of intangible assets
Impairment of intangible assets and related costs
Restructuring charges

Operating income
Non-operating income (expense):
Interest income
Interest expense
Gain on investments, net
Other, net
Total non-operating income (expense)
Earnings from continuing operations before income taxes
Provision for income taxes
Earnings from continuing operations
Discontinued Operations:
Earnings from discontinued operations, net of applicable income tax expense of $6.9 million and $0.5 million for the years ended December 31, 2013 and 2012, respectively
Loss on sale of discontinued operation, net of applicable income tax expense (benefit) of $1.3 million and $(110.3) million for the years ended December 31, 2014 and 2013, respectively
Discontinued operations
Net earnings
Net earnings attributable to noncontrolling interest
Net earnings attributable to Allergan, Inc.
Earnings per share attributable to Allergan, Inc. stockholders:
Basic earnings per share attributable to Allergan, Inc. stockholders:
Continuing operations (in dollars per share)
Discontinued operations (in dollars per share)
Net basic earnings per share attributable to Allergan, Inc. stockholders (in dollars per share)
Diluted earnings per share attributable to Allergan, Inc. stockholders:
Continuing operations (in dollars per share)
Discontinued operations (in dollars per share)
Net diluted earnings per share attributable to Allergan, Inc. stockholder (in dollars per share)

Comments